Skip to content

Replimune Group REPL Other income, net (Note 6)

Other income, net (Note 6) at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$12K+76.0%
CG Oncology logo
CG OncologyCGON
-$101K-2,120%
Erasca, Inc. logo
Erasca, Inc.ERAS
$22K+129%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$5.3M-32.1%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.08M+0.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's other income, net (note 6)?
Replimune Group (REPL) reported other income, net (note 6) of -$580K in Q4 2025.
How has Replimune Group's other income, net (note 6) changed year-over-year?
Replimune Group's other income, net (note 6) increased by 82.3% year-over-year, from -$3.28M to -$580K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.